ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds have met the product profile requirements, set by both Exscientia and Sanofi, to enable a transition to the lead optimisation phase within the collaboration. Both programmes have also shown a high level of differentiation in earl.

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

Recursion Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) , relating to its proposed merger with Exscientia PLC.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain. “As our precision-designed LSD1 and MALT1 inhibitors continue to progress towards the clinic, we are excited to share new preclinical data from both programmes,” said David Hallett, Ph.D., interim Chief Executive Officer and Chief Scientific Officer of Exscientia. “These posters, as well as an add.

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

SAN MATEO, Calif.--(BUSINESS WIRE)--Brilliant, the designer and manufacturer of innovative smart home controls and home automation systems shares its acquisition by Almeida Strategic Investments, led by brothers Evan and Michael Almeida, in partnership with David Blum, owner of Cullinan Holdings. The private investment fuels the next generation of innovation for Brilliant's award-winning smart home controls, switches, and plugs trusted in thousands of homes in North America. The new organizatio.

Brilliant NextGen Will Expand Solutions for Builders Through its Acquisition by Private Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Methode Electronics, Inc. (MEI) Investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Methode Electronics, Inc. (MEI) Investors

ANNAPOLIS, Md.--(BUSINESS WIRE)--BreachBits is pleased to announce its collaboration with SecurityStudio for 2024. SecurityStudio is a cyber risk management platform that focuses on holistic information security for your organization, team, and vendors. BreachBits delivers security and compliance capabilities via the BreachRisk platform. BreachRisk leverages AI and automation to provide scalable cyber risk monitoring and testing from an attacker's perspective. These solutions empower organizati.

BreachBits and SecurityStudio Collaborate to Enhance Virtual CISO Credentials and Automated Capabilities

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has commented that the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of “a+” (Excellent) of American National Insurance Company (ANICO) and its affiliates, American National Life Insurance Company of Texas and American National Life Insurance Company of New York (Glenmont, NY), collectively known as American National Group (ANG), remain unchanged following an announced coinsurance arrangement whereby ANG will cede $3.5.

AM Best Comments on Credit Ratings of American National Group's Members Following Announced Coinsurance Agreement With Reinsurance Group of America, Incorporated

DALLAS--(BUSINESS WIRE)--Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, is proud to announce that the Dallas Business Journal has named its Dallas office as one of its Best Places to Work for the second year in a row. The annual list recognizes North Texas companies that have gone above and beyond to create an exemplary workplace, and Suffolk's consecutive wins highlight the growing impact the local team has on the region. Suffolk's Dall.

Suffolk Texas Named Best Place to Work for Two Consecutive Years

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST). A live webcast of the fireside chat will be available on the Company's website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of.

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2024, are summarised below. “Last week, we announced that Exscientia entered into a definitive agreement to combine with Recursion Pharmaceuticals,” said David Hallett, Ph.D., interim Chief Executive Officer and Chief Scientific Officer of Exscientia. “When we bring together our platforms at.

Exscientia Business Update for Second Quarter and First Half 2024

On Thursday, Exscientia plc EXAI agreed to merge with Recursion Pharmaceuticals Inc. RXRX.

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal, according to a statement seen by Reuters.

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. Recruitment for the trial is progressing well with monotherapy dose escalation data o.

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Marsh & McLennan

PRINCETON, N.J.--(BUSINESS WIRE)--Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, today publicly announced the appointment of Eric Major as the company's Chairman of the Board. "We are pleased to be expanding Orthobond's Board of Directors with the appointment of Eric, whose vast experience in the medical device space and in driving strategic growth will be an instrumental part of Orthobond's future,”.

Orthobond Expands its Board of Directors with Appointment of Eric Major as Chairman

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud provider's artificial intelligence (AI) and machine learning (ML) services to power its platform for end-to-end drug discovery and automation. Exscientia's platform uses generative AI models and the scalability and flexibility of AWS to securely, quickly and efficiently design drug candidates that aim to better target specific diseases and.

Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery

ChargePoint Holdings

Viridian Therapeutics

Small-cap stocks, typically valued between $300 million and $2 billion, often promise notable growth potential and superior long-term returns. Now, with interest rate cuts on the horizon, investors are speculating which high-growth small-cap stocks may thrive.

3 Small-Cap Stocks With Explosive 2X Growth Potential

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=87416&wire=1 or contact Joseph E. Levi, Esq.

Exscientia plc Class Action: Levi & Korsinsky Reminds Exscientia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 25, 2024 - EXAI

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=87422&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by June 25, 2024 Deadline to Join Class Action Against Exscientia plc(EXAI)

LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

Exscientia Plc Investors With Losses Are Encouraged By The Schall Law Firm To Start Communication Be Aware Of The Deadline In This Case

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=87396&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

LOS ANGELES--(BUSINESS WIRE)--EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm.

EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=87392&wire=1 or contact Joseph E. Levi, Esq.

Investors in Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI

NEW YORK , June 25, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Exscientia p.l.c. ("Exscientia" or "the Company") (NASDAQ:EXAI) and certain of its officers.

FINAL EXAI DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Exscientia p.l.c. Investors to Join the Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=87325&wire=1 or contact Joseph E. Levi, Esq.

News for ExScientia Ltd Stock (EXAI)